Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed May 8, 2023
- Accession no.
- 0001447362-23-000069
- Filed
- May 8, 2023
- Trade date
- May 4, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 14 non-derivative transactions. Open-market sales total $181.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2023 | Common Stock | SSaleDisposed | −1,660 | $21.43F2 | −$35,573.8 | 153,113 | Direct | |
| May 4, 2023 | Common Stock | SSaleDisposed | −830 | $21.43F2 | −$17,786.9 | 114,120 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −830 | $21.43F2 | −$17,786.9 | 103,015 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −414 | $21.43F2 | −$8,872.02 | 20,501 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −415 | $21.43F2 | −$8,893.45 | 20,501 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −414 | $21.43F2 | −$8,872.02 | 20,501 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −414 | $21.43F2 | −$8,872.02 | 20,494 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −1,132 | $21.94F9 | −$24,836.08 | 151,981 | Direct | |
| May 4, 2023 | Common Stock | SSaleDisposed | −566 | $21.94F9 | −$12,418.04 | 113,554 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −566 | $21.94F9 | −$12,418.04 | 102,449 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −283 | $21.94F9 | −$6,209.02 | 20,218 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −283 | $21.94F9 | −$6,209.02 | 20,218 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −283 | $21.94F9 | −$6,209.02 | 20,218 | Indirect | |
| May 4, 2023 | Common Stock | SSaleDisposed | −282 | $21.94F9 | −$6,187.08 | 20,212 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $20.810 to $21.800, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $21.815 to $22.170 inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.